Clear 523 Results Filter Filter Results Type: Press Release Abiomed Announces Q1 FY 2020 Revenue of $208 Million and 292% Operating Margin Type: Press Release Abiomed First Quarter Fiscal 2020 Earnings and Conference Call Notification Type: Press Release Impella Featured as an Innovative Technology at US Capitol Event Showcasing Improvements to Women’s Health Type: Press Release Abiomed to Present at Upcoming Investor Conferences Type: Press Release FDA Confirms Impella RP is Safe and Effective Only Right-Sided Device with FDA Approval Type: Press Release National Cardiogenic Shock Initiative (NCSI) with Impella Best Practices Demonstrates 72% Survival with 98% Native Heart Recovery Type: Press Release Impella SmartAssist Platform Launches at SCAI Designed to Further Improve Patient Outcomes Type: Press Release FDA Approves Impella 50 and Impella LD Extended Duration of Use to 14 Days for Cardiogenic Shock Derived from AMI or Cardiomyopathy Type: Press Release FDA Approves Initiation of STEMI DTU Pivotal Randomized Controlled Trial Type: Press Release Abiomed Announced Q4 FY 2019 Revenue of $207 Million and 316% Operating Margin … 2 3 4 5 …
